NEWS HIGHLIGHTSMedia Articles Related to Azilect (Rasagiline)
Findings That Should Speed The Development Of Drugs For Parkinson's Disease
Source: Health News from Medical News Today [2009.11.19]
Australian scientists have significantly advanced our understanding of dopamine release from nerve cells, findings that should speed the development of more effective drugs for treating Parkinson's Disease. People with Parkinson's Disease suffer from muscle rigidity, tremor, a slowing of physical movement and, in extreme cases, a loss of physical movement.
Progression Of Parkinson's Disease May Be Prevented By Widely Used Cholesterol-Lowering Drug
Source: Statins News From Medical News Today [2009.10.31]
Simvastatin, a commonly used, cholesterol-lowering drug, may prevent Parkinson's disease from progressing further. Neurological researchers at Rush University Medical Center conducted a study examining the use of the FDA-approved medication in mice with Parkinson's disease and found that the drug successfully reverses the biochemical, cellular and anatomical changes caused by the disease.
Avian Influenza Strain Primes Brain For Parkinson's Disease
Source: Bird Flu / Avian Flu News From Medical News Today [2009.08.11]
At least one strain of the H5N1 avian influenza virus leaves survivors at significantly increased risk for Parkinson's disease and possibly other neurological problems later in life, according to new research from St. Jude Children's Research Hospital.
Parkinson's Disease
Source: MedicineNet Amyotrophic Lateral Sclerosis Specialty [2009.04.28]
Title: Parkinson's Disease
Category: Diseases and Conditions
Created: 12/31/1997
Last Editorial Review: 4/28/2009
NC State Researchers Advance Understanding Of Stem Cells
Source: Genetics News From Medical News Today [2009.11.19]
Researchers from North Carolina State University have identified a gene that tells embryonic stem cells in the brain when to stop producing nerve cells called neurons. The research is a significant advance in understanding the development of the nervous system, which is essential to addressing conditions such as Parkinson's disease, Alzheimer's disease and other neurological disorders.
Published Studies Related to Azilect (Rasagiline)
A double-blind, delayed-start trial of rasagiline in Parkinson's disease. [2009.09.24]
BACKGROUND: A therapy that slows disease progression is the major unmet need in Parkinson's disease... CONCLUSIONS: Early treatment with rasagiline at a dose of 1 mg per day provided benefits that were consistent with a possible disease-modifying effect, but early treatment with rasagiline at a dose of 2 mg per day did not. Because the two doses were associated with different outcomes, the study results must be interpreted with caution. (ClinicalTrials.gov number, NCT00256204.) 2009 Massachusetts Medical Society
Role of rasagiline in treating Parkinson's disease: Effect on disease progression. [2009.08]
Rasagiline is a second generation, selective, irreversible monoamine oxidase type B (MAO-B) inhibitor. It has demonstrated efficacy in monotherapy for early Parkinson's disease (PD) patients in one large randomized, placebo-controlled trial (TVP-1012 in Early Monotherapy for Parkinson's Disease Outpatients), and has shown ability to reduce off time in more advanced PD patients with motor fluctuations in two large placebo-controlled trials (Parkinson's Rasagiline: Efficacy and Safety in the Treatment of "Off", and Lasting Effect in Adjunct Therapy With Rasagiline Given Once Daily).
Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease. [2009.03.15]
The purpose of this study to compare the long-term clinical outcome of early versus delayed rasagiline treatment in early Parkinson's disease (PD). Subjects (N = 404) were randomly assigned to initial treatment with rasagiline (early-start group) or placebo for 6 months followed by rasagiline (delayed-start group) in the TEMPO study...
A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristics. [2008.11.15]
A neuroprotective therapy is the single most important unmet medical need in Parkinson's disease.We here describe the rationale for the study and baseline characteristics of the 1,176 patients who have been enrolled into the trial.
A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): Rationale, design, and baseline characteristics. [2008.10.19]
A neuroprotective therapy is the single most important unmet medical need in Parkinson's disease.We here describe the rationale for the study and baseline characteristics of the 1,176 patients who have been enrolled into the trial.
Clinical Trials Related to Azilect (Rasagiline)
A Non-Blinded Study Demonstrating the Effectiveness and Safety of Azilect Alone or in Combination Therapy in Parkinson's Disease [Completed]
Patients with Parkinson's Disease (PD) will be divided into 2 groups at each study center at
their first visit based on the drugs they are taking for their PD:
- Group 1 Patients using Azilect and no other therapy.
- Group 2 Azilect in combination with other medications like Levodopa, Mirapex, or
Requip.
Rasagiline and Apathy in Parkinson's Disease [Recruiting]
The purpose of this study is to determine whether rasagiline is effective in the treatment
of apathy in patients with Parkinson's disease.
The Effects of Rasagiline on Cognitive Deficits Associated With Parkinson's Disease [Recruiting]
The objective of the study is to assess the effects of rasagiline on cognitive functions in
patient with Parkinson's disease. Patients on any dopaminergic medications will be assigned
to receive rasagiline 1 mg or placebo over 3 months. Cognitive functions will be assessed by
selected neuropsychological tests representing each cognitive domain.
Clinical Trial to Assess Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients With Multiple System Atrophy of the Parkinsonian Subtype (MSA-P) [Not yet recruiting]
To test the clinical effect of rasagiline on subjects with MSA of the parkinsonian subtype.
Olfaction in Patients With Parkinson's Disease Following Treatment With Rasagiline [Recruiting]
There is convincing evidence from numerous studies using both psychophysical and
electrophysiological approaches that olfaction is markedly reduced in Parkinson´s disease
(PD). Data on the prevalence of olfactory dysfunction in PD however, range from 45% and 49%
in the pioneering studies of Ansari & Johnson, and Ward, respectively, up to 74% in the work
of Hawkes et al., or as high as 90% in a study published by Doty et al. Quality of life,
safety, and interpersonal relations, as well as food behavior/nutritional intake are
severely altered in a large proportion of patients with olfactory loss. Thus, the same can
be assumed in patients with Parkinson's disease. If it was possible to improve olfactory
function this would appear as a significant effect in patients with Parkinson's disease.
Provided the study would reveal an improvement of olfactory function following therapy with
rasagiline, this would have tremendous worldwide impact on the use of this drug. Considering
the frequency of PD a very large number of patients would benefit from these findings,
especially in terms of quality of life.
|
